Do Analysts Expect Vertex Pharmaceuticals Incorporated (VRTX) Stock to Rise After It Has Risen 14.23% in a Month?

InvestorsObserver is giving Vertex Pharmaceuticals Incorporated (VRTX) an Analyst Rating Rank of 29, meaning VRTX is ranked higher by analysts than 29% of stocks. The average price target for VRTX is $252 and analyst’s rate the stock as a Buy.

Wall Street analysts are rating VRTX a Buy today. Find out what this means to you and get the rest of the rankings on VRTX!

See Full VRTX Report

Why are Analyst Ratings Important?

Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers. InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.

What's Happening With Vertex Pharmaceuticals Incorporated Stock Today?

Vertex Pharmaceuticals Incorporated (VRTX) stock is trading at $207.22 as of 1:29 PM on Thursday, Dec 2, an increase of $2.22, or 1.08% from the previous closing price of $205.00. The stock has traded between $201.51 and $208.16 so far today. Volume today is 1,776,183 compared to average volume of 2,018,958. Click Here to get the full Stock Report for Vertex Pharmaceuticals Incorporated stock.